Start Your Journey to Early Vascular Care
AirSeal CardioVascular is a medical diagnostics company that aims to transform how doctors and hospital systems diagnose individuals with peripheral artery disease (PAD) and other cardiovascular disease indications. The AirSeal patented diagnostic technology platform has the potential to dramatically improve the lives of hundreds of millions of people worldwide.
We have developed an innovative & already patented serum-based biomarker technology that can diagnose CVD with high accuracy in both women and men. Our product PADGuardTM is a rapid, multi-well, high through-put immunoassay and the first blood test to diagnose PAD.
cFAS is produced by the liver and circulates in the blood stream of individuals who are more likely to have underlying CVD (both individuals with and without symptoms). cFAS was discovered at Washington University School of Medicine and has been investigated in multiple published clinical trials.
We recently validated the cFAS diagnostic accuracy in three independent clinical trials in >500 women and men. The results of prior clinical trials are published/pending publication in reputable peer-reviewed scientific/medical journals.
AirSeal is advancing early, accurate diagnosis of cardiovascular diseases through innovative biomarker technology.